This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need, affordable pricing, and working of patents in India.
Read more about Lee Pharma v. AstraZeneca- An unfinished Patent StoryTag: Pharmaceutical patents
Intellectual Property (IP) in India: A Decade of Progress Part 11
This post presents a statistical overview of pharmaceutical patents in India over the past decade, focusing on trends and key contributors. It objectively discusses the impact of legal changes and regulatory measures on patent filings in the pharmaceutical sector.
Read more about Intellectual Property (IP) in India: A Decade of Progress Part 11Roche loses again
The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical companies.
Read more about Roche loses againPatent Infringement Claim on Cancer Treatment Drug
The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.
Read more about Patent Infringement Claim on Cancer Treatment Drug‘Killead’s Patent Application Killed by the Indian Patent Office!
Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.
Read more about ‘Killead’s Patent Application Killed by the Indian Patent Office!Roche’s backbone rendered brittle by Indian Patent Office
The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects of Indian pharmaceutical patent law and its impact on international drug companies.
Read more about Roche’s backbone rendered brittle by Indian Patent OfficeSpecial 301 Report: Chapter V. Inventive Step & 3(d) – Comprehending Apprehension or Apprehending Comprehension?
This post critically examines whether Section 3d serves as an extension of the inventive step analysis or as a separate requirement under Indian patent law. It discusses the legal and judicial perspectives on TRIPs compliance and the nuanced challenges in pharmaceutical patentability.
Read more about Special 301 Report: Chapter V. Inventive Step & 3(d) – Comprehending Apprehension or Apprehending Comprehension?The 3D Effect of Novartis Case on Genetic Inventions
The Novartis case established a strict test for therapeutic efficacy under Section 3(d) of the Indian Patents Act, influencing the patentability of genetic inventions. This post examines the impact on gene sequence patents and the ongoing legal debate regarding their compliance with Indian patent law.
Read more about The 3D Effect of Novartis Case on Genetic Inventions